Drug-induced liver injury due to cancer chemotherapeutic agents

Seminars in Liver Disease

Volumn 34, Issue 2, 2014, Pages 162-171

  Bahirwani, Ranjeeta ^a   Reddy, K Rajender ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

chemotherapy; drug induced liver injury; hepatic dysfunction; hepatotoxicity; liver failure

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DNA TOPOISOMERASE INHIBITOR; MONOCLONAL ANTIBODY; PHOSPHOTRANSFERASE INHIBITOR; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VINCA ALKALOID; ANTINEOPLASTIC ANTIMETABOLITE; PROTEIN KINASE INHIBITOR; TAXOID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG MECHANISM; GENETIC SUSCEPTIBILITY; HEPATITIS B; HEPATITIS VIRUS; HUMAN; IMMUNOCOMPROMISED PATIENT; IRRADIATION; LIVER CELL DAMAGE; LIVER FUNCTION; LIVER SINUSOID; LIVER VENOOCCLUSIVE DISEASE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RADIATION INJURY; TOXIC HEPATITIS; DRUG-INDUCED LIVER INJURY; METABOLISM;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; DRUG-INDUCED LIVER INJURY; HUMANS; PLATINUM COMPOUNDS; PROTEIN KINASE INHIBITORS; TAXOIDS; TOPOISOMERASE INHIBITORS;

EID: 84901816347     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1375957     Document Type: Article

References (131)

1. Lewis J. H. Drug-induced liver disease. Med Clin North Am: 2000; 84 5 1275 1311, x
2. King P. D., Perry M. C. Hepatotoxicity of chemotherapy. Oncologist: 2001; 6 2 162 176 (Pubitemid 32323455)
3. Larrey D. Drug-induced liver diseases. J Hepatol: 2000; 32 (1, Suppl) 77 88 (Pubitemid 30123626)
4. National Cancer Institute Cancer Therapy Evaluation Program. National Cancer Institute; 2005;. Available at: http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/newadverse-2006.pdf. Accessed October 30, 2013
5. Lee W. M. Drug-induced hepatotoxicity. N Engl J Med: 1995; 333 17 1118 1127
6. Ceci G., Bella M., Melissari M., Gabrielli M., Bocchi P., Cocconi G. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? Cancer: 1988; 61 10 1988 1991
7. Asbury R. F., Rosenthal S. N., Descalzi M. E., Ratcliffe R. L., Arseneau J. C. Hepatic veno-occlusive disease due to DTIC. Cancer: 1980; 45 10 2670 2674 (Pubitemid 10105326)
8. Le Couteur D. G., Cogger V. C., Markus A. M., et al. Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology: 2001; 33 3 537 543 (Pubitemid 32185214)
9. Diehl A. M. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol: 2002; 282 1 G1 G5
10. Veteläinen R., van Vliet A. K., van Gulik T. M. Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy. Ann Surg: 2007; 245 1 44 50 (Pubitemid 46035434)
11. DeLeve L. D., Shulman H. M., McDonald G. B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis: 2002; 22 1 27 42
12. Shulman H. M., Fisher L. B., Schoch H. G., Henne K. W., McDonald G. B. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology: 1994; 19 5 1171 1181
13. McDonald G. B., Hinds M. S., Fisher L. D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med: 1993; 118 4 255 267 (Pubitemid 23046384)
14. Dix S. P., Wingard J. R., Mullins R. E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant: 1996; 17 2 225 230 (Pubitemid 26057312)
15. Marsh J. C. Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication. Hepatology: 1989; 9 5 790 792
16. Morgan M., Dodds A., Atkinson K., Szer J., Downs K., Biggs J. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol: 1991; 77 4 529 534
17. Gill R. A., Onstad G. R., Cardamone J. M., Maneval D. C., Sumner H. W. Hepatic veno-occlusive disease caused by 6-thioguanine. Ann Intern Med: 1982; 96 1 58 60 (Pubitemid 12205519)
18. Stoneham S., Lennard L., Coen P., Lilleyman J., Saha V. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol: 2003; 123 1 100 102 (Pubitemid 37222763)
19. Joensuu H., Söderström K. O., Nikkanen V. Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report. Cancer: 1986; 58 7 1437 1440 (Pubitemid 16016825)
20. Houghton A. N., Shafi N., Rickles F. R. Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease: a case report. Cancer: 1979; 44 6 2324 2329 (Pubitemid 10210866)
21. Julie C., Lutz M., Aust D. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983. J Clin Oncol: 2007; 25: abstract 241
22. Nakano H., Oussoultzoglou E., Rosso E., et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg: 2008; 247 1 118 124
23. Guha C., Kavanagh B. D. Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol: 2011; 21 4 256 263
24. Reed G. B. Jr, Cox A. J. Jr. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol: 1966; 48 4 597 611
25. Hansen M. M., Ranek L., Walbom S., Nissen N. I. Fatal hepatitis following irradiation and vincristine. Acta Med Scand: 1982; 212 3 171 174 (Pubitemid 12020951)
26. Kun L. E., Camitta B. M. Hepatopathy following irradiation and adriamycin. Cancer: 1978; 42 1 81 84 (Pubitemid 9031848)
27. Tefft M., Traggis D., Filler R. M. Liver irradiation in children: acute changes with transient leukopenia and thrombocytopenia. Am J Roentgenol Radium Ther Nucl Med: 1969; 106 4 750 765
28. Ishak K. G., Zimmerman H. J. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am: 1995; 24 4 759 786 (Pubitemid 26107529)
29. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol: 1990; 11 2 272 276
30. Maria V. A., Victorino R. M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology: 1997; 26 3 664 669 (Pubitemid 27392358)
31. Jakse G., Madersbacher H. [Stauffer's syndrome. Reversible hepatic dysfunction in renal cell carcinoma (author's transl)]. Wien Klin Wochenschr: 1978; 90 8 268 270 (Pubitemid 8296776)
32. Chalasani N., Fontana R. J., Bonkovsky H. L., et al. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology: 2008; 135 6 1924 1934, e1-e4
33. Yeo W., Johnson P. J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology: 2006; 43 2 209 220
34. Lok A. S., McMahon B. J. Chronic hepatitis B: update 2009. Hepatology: 2009; 50 3 661 662
35. Vento S., Cainelli F., Mirandola F., et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet: 1996; 347 8994 92 93 (Pubitemid 26017855)
36. de Pree C., Giostra E., Galetto A., Perrin L., Zulian G. B. Hepatitis C virus acute exacerbation during chemotherapy and radiotherapy for oesophageal carcinoma. Ann Oncol: 1994; 5 9 861 862 (Pubitemid 24341884)
37. Torres H. A., Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol: 2012; 9 3 156 166
38. Frickhofen N., Wiesneth M., Jainta C., et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood: 1994; 83 7 1998 2004
39. Strasser S. I., Myerson D., Spurgeon C. L., et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology: 1999; 29 6 1893 1899 (Pubitemid 29247066)
40. Khan S., Ramwani J. J., O'Brien P. J. Hepatocyte toxicity of mechlorethamine and other alkylating anticancer drugs. Role of lipid peroxidation. Biochem Pharmacol: 1992; 43 9 1963 1967
41. Brühl P., Günther U., Hoefer-Janker H., Hüls W., Scheef W., Vahlensieck W. Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours. Int J Clin Pharmacol Biopharm: 1976; 14 1 29 39
42. Paschke R., Worst P., Brust J., Queisser W. [Hepatotoxicity with etoposide-ifosfamide combination therapy]. Onkologie: 1988; 11 6 273 275
43. Falkson G., Hunt M., Borden E. C., Hayes J. A., Falkson C. I., Smith T. J. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs: 1992; 10 4 337 343 (Pubitemid 23008985)
44. Aubrey D. A. Massive hepatic necrosis after cyclophosphamide. BMJ: 1970; 3 5722 588
45. Goldberg J. W., Lidsky M. D. Cyclophosphamide-associated hepatotoxicity. South Med J: 1985; 78 2 222 223 (Pubitemid 15130360)
46. Bacon A. M., Rosenberg S. A. Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. Ann Intern Med: 1982; 97 1 62 63
47. Floyd J., Mirza I., Sachs B., Perry M. C. Hepatotoxicity of chemotherapy. Semin Oncol: 2006; 33 1 50 67 (Pubitemid 43214486)
48. Morris L. E., Guthrie T. H. Jr. Busulfan-induced hepatitis. Am J Gastroenterol: 1988; 83 6 682 683
49. Lee J. H., Choi S. J., Lee J. H., et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol: 2005; 84 5 321 330
50. Giralt S., Thall P. F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood: 2001; 97 3 631 637 (Pubitemid 32113394)
51. Rai K. R., Peterson B. L., Appelbaum F. R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med: 2000; 343 24 1750 1757
52. Romagnuolo J., Sadowski D. C., Lalor E., Jewell L., Thomson A. B. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol: 1998; 12 7 479 483 (Pubitemid 28495463)
53. Small P., Lichter M. Probable azathioprine hepatotoxicity: a case report. Ann Allergy: 1989; 62 6 518 520 (Pubitemid 19159030)
54. Barrowman J. A., Kutty P. K., Ra M. U., Huang S. N. Sclerosing hepatitis and azathioprine. Dig Dis Sci: 1986; 31 2 221 222
55. Ménard D. B., Gisselbrecht C., Marty M., Reyes F., Dhumeaux D. Antineoplastic agents and the liver. Gastroenterology: 1980; 78 1 142 164 (Pubitemid 10159403)
56. Shorey J., Schenker S., Suki W. N., Combes B. Hepatotoxicity of mercaptopurine. Arch Intern Med: 1968; 122 1 54 58
57. McIlvanie S. K., MacCarthy J. D. Hepatitis in association with prolonged 6-mercaptopurine therapy. Blood: 1959; 14 1 80 90
58. Pizzuto J., Avilés A., Ramos E., Cervera J., Aguirre J. Cytosine arabinoside induced liver damage: histopathologic demonstration. Med Pediatr Oncol: 1983; 11 4 287 290 (Pubitemid 13018400)
59. George C. B., Mansour R. P., Redmond J. III, Gandara D. R. Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer: 1984; 54 11 2360 2362 (Pubitemid 15223373)
60. Koren G., Beatty K., Seto A., Einarson T. R., Lishner M. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother: 1992; 26 3 363 371
61. Bateman J. R., Pugh R. P., Cassidy F. R., Marshall G. J., Irwin L. E. 5-fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer: 1971; 28 4 907 913
62. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol: 2006; 24 31 4983 4990 (Pubitemid 46631400)
63. Twelves C., Glynne-Jones R., Cassidy J., et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res: 1999; 5 7 1696 1702 (Pubitemid 29334448)
64. Doria M. I. Jr, Shepard K. V., Levin B., Riddell R. H. Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR. Cancer: 1986; 58 4 855 861 (Pubitemid 16035283)
65. Chang A. E., Schneider P. D., Sugarbaker P. H., Simpson C., Culnane M., Steinberg S. M. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg: 1987; 206 6 685 693 (Pubitemid 18056182)
66. Hohn D., Melnick J., Stagg R., et al. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol: 1985; 3 1 98 102 (Pubitemid 15187703)
67. Shepard K. V., Levin B., Karl R. C., et al. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol: 1985; 3 2 161 169 (Pubitemid 15153756)
68. Krivoy N., Raz R., Carter A., Alroy G. Reversible hepatic veno-occlusive disease and 6-thioguanine. Ann Intern Med: 1982; 96 (6 Pt 1): 788 (Pubitemid 12029354)
69. Larrey D., Fréneaux E., Berson A., et al. Peliosis hepatis induced by 6-thioguanine administration. Gut: 1988; 29 9 1265 1269
70. Aapro M. S., Martin C., Hatty S. Gemcitabine-a safety review. Anticancer Drugs: 1998; 9 3 191 201
71. Teusink A. C., Hall P. D. Toxicities of gemcitabine in patients with severe hepatic dysfunction. Ann Pharmacother: 2010; 44 4 750 754
72. Podurgiel B. J., McGill D. B., Ludwig J., Taylor W. F., Muller S. A. Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin Proc: 1973; 48 11 787 792
73. Evans W. E., Pratt C. B. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther: 1978; 23 1 68 72 (Pubitemid 8290412)
74. Avilés A., Herrera J., Ramos E., Ambriz R., Aguirre J., Pizzuto J. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med: 1984; 108 11 912 913 (Pubitemid 15202908)
75. Johnson P. J., Dobbs N., Kalayci C., et al. Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer: 1992; 65 5 751 755
76. Chan K. K., Chlebowski R. T., Tong M., Chen H. S., Gross J. F., Bateman J. R. Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res: 1980; 40 4 1263 1268 (Pubitemid 10135842)
77. Erichsen C., Jönsson P. E. Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma. J Surg Oncol: 1984; 27 4 268 270 (Pubitemid 15179697)
78. McClay E., Lusch C. J., Mastrangelo M. J. Allergy-induced hepatic toxicity associated with dacarbazine. Cancer Treat Rep: 1987; 71 2 219 220 (Pubitemid 17030164)
79. Ludwig R., Weirich A., Abel U., Hofmann W., Graf N., Tournade M. F. Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH. Med Pediatr Oncol: 1999; 33 5 462s 469
80. Lazarus H. M., Gottfried M. R., Herzig R. H., et al. Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer: 1982; 49 9 1789 1795 (Pubitemid 12153448)
81. Crooke S. T., Bradner W. T. Mitomycin C: a review. Cancer Treat Rev: 1976; 3 3 121 139
82. Hirth J., Watkins P. B., Strawderman M., Schott A., Bruno R., Baker L. H. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res: 2000; 6 4 1255 1258 (Pubitemid 30226205)
83. Minami H., Kawada K., Sasaki Y., et al. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci: 2009; 100 1 144 149
84. National Institute of Health DailyMed. Available at: http://dailymed.nlm. nih.gov/dailymed/drugInfo.cfm. Accessed October 30, 2013
85. Desai Z. R., Van den Berg H. W., Bridges J. M., Shanks R. G. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol: 1982; 8 2 211 214 (Pubitemid 12081391)
86. Hohneker J. A. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol: 1994; 21 (5, Suppl 10) 42 46, discussion 46-47
87. Van den Berg H. W., Desai Z. R., Wilson R., Kennedy G., Bridges J. M., Shanks R. G. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol: 1982; 8 2 215 219 (Pubitemid 12081392)
88. Tran A., Housset C., Boboc B., Tourani J. M., Carnot F., Berthelot P. Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. J Hepatol: 1991; 12 1 36 39
89. Johnson D. H., Greco F. A., Wolff S. N. Etoposide-induced hepatic injury: a potential complication of high-dose therapy. Cancer Treat Rep: 1983; 67 11 1023 1024 (Pubitemid 14208705)
90. Stewart C. F., Arbuck S. G., Fleming R. A., Evans W. E. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol: 1990; 8 11 1874 1879 (Pubitemid 20382351)
91. Raymond E., Boige V., Faivre S., et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol: 2002; 20 21 4303 4312 (Pubitemid 35266290)
92. Fernandez F. G., Ritter J., Goodwin J. W., Linehan D. C., Hawkins W. G., Strasberg S. M. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg: 2005; 200 6 845 853 (Pubitemid 40744790)
93. Creemers G. J., Lund B., Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev: 1994; 20 1 73 96 (Pubitemid 24043771)
94. Hill J. M., Loeb E., MacLellan A., Hill N. O., Khan A., King J. J. Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep: 1975; 59 3 647 659
95. Hruban R. H., Sternberg S. S., Meyers P., Fleisher M., Menendez-Botet C., Boitnott J. K. Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Invest: 1991; 9 3 263 268
96. Christian M. C. Two toxicities associated with carboplatin use: A. gross hematuria B. hepatic veno-occlusive disease. Department of Health & Human Services Bulletin. Bethesda, MD National Institutes of Health, National Cancer Institute: 1989
97. Pollera C. F., Ameglio F., Nardi M., Vitelli G., Marolla P. Cisplatin-induced hepatic toxicity. J Clin Oncol: 1987; 5 2 318 319
98. Fakih M. G. 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction. Oncology: 2004; 67 3-4 222 224 (Pubitemid 39551705)
99. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol: 2004; 15 3 460 466 (Pubitemid 38444550)
100. Nordstrom B. H., Fraeman K. H., Luo W. Liver function test abnormalities in patients treated with small molecule tyrosine kinase inhibitors. Paper presented at: International Society for Pharmacoepidemiology Annual Meeting; August 19-22,: 2010;; Brighton, UK
101. Chang J., Rand M., Blumenthal G. FDA evaluation of hepatotoxicity related to tyrosine kinase inhibitors. J Clin Oncol: 2011; 29 3106
102. Tujios S., Fontana R. J. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol: 2011; 8 4 202 211
103. Miller A. A., Murry D. J., Owzar K., et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol: 2007; 25 21 3055 3060 (Pubitemid 47218052)
104. Liu W., Makrauer F. L., Qamar A. A., Jänne P. A., Odze R. D. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol: 2007; 5 8 917 920 (Pubitemid 47127027)
105. Pellegrinotti M., Fimognari F. L., Franco A., Repetto L., Pastorelli R. Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. Ann Pharmacother: 2009; 43 3 542 545
106. Ho C., Davis J., Anderson F., Bebb G., Murray N. Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J Clin Oncol: 2005; 23 33 8531 8533
107. Kikuchi S., Muroi K., Takahashi S., et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk Lymphoma: 2004; 45 11 2349 2351 (Pubitemid 39504334)
108. O'Brien S. G., Guilhot F., Larson R. A., et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med: 2003; 348 11 994 1004 (Pubitemid 36302244)
109. Cross T. J., Bagot C., Portmann B., Wendon J., Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol: 2006; 81 3 189 192
110. Ferrero D., Pogliani E. M., Rege-Cambrin G., et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica: 2006;; 91 (6, Suppl) ECR27
111. Moy B., Rappold E., Williams L. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. J Clin Oncol: 2009; 27 1043
112. Spraggs C. F., Budde L. R., Briley L. Hyperbilirubinemia in lapatinib treated patients is associated with Gilbert's syndrome UGT1A1 polymorphism. Cancer Res: 2009; 69 24 69
113. Spraggs C. F., Budde L. R., Briley L. P., et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol: 2011; 29 6 667 673
114. Sternberg C. N., Davis I. D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol: 2010; 28 6 1061 1068
115. Xu C. F., Reck B. H., Xue Z., et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer: 2010; 102 9 1371 1377
116. Shibata S. I., Chung V., Synold T. W., et al. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res: 2013; 19 13 3631 3639
117. Xu C. F., Reck B. H., Goodman V. L., et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol: 2011; 54 6 1237 1243
118. Iclusig. [package insert]. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/203469lbl.pdf. Accessed October 30, 2013
119. Stivarga. [package insert]. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/203085lbl.pdf Accessed October 30, 2013
120. Sutent [package insert]. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/021938s13s17s18lbl.pdf. Accessed October 30, 2013
121. Fairfax B. P., Pratap S., Roberts I. S., et al. Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. BMC Cancer: 2012; 12 590
122. Miller A. A., Murry D. J., Owzar K., et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol: 2009; 27 11 1800 1805
123. Avastin [package insert]. South San Francisco, CA Genentech: 2004
124. Dent S., Oyan B., Honig A., Mano M., Howell S. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treat Rev: 2013; 39 6 622 631
125. Wolchok J. D., Neyns B., Linette G., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol: 2010; 11 2 155 164
126. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med: 2011; 364 26 2517 2526
127. Weber J. S., Kähler K. C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol: 2012; 30 21 2691 2697
128. Pectasides D., Dafni U., Bafaloukos D., et al. Randomized phase III study of 1-month versus 1-year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol: 2009; 27 6 939 944
129. Shindo M., Di Bisceglie A. M., Hoofnagle J. H. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology: 1992; 102 4 Pt 1 1406 1408
130. Nakagawa K., Miller F. N., Sims D. E., Lentsch A. B., Miyazaki M., Edwards M. J. Mechanisms of interleukin-2-induced hepatic toxicity. Cancer Res: 1996; 56 3 507 510 (Pubitemid 26043647)
131. Fisher B., Keenan A. M., Garra B. S., et al. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol: 1989; 7 12 1852 1862 (Pubitemid 20014333)